Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 710

Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA

Prof Mohamed Salem speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the
recent advances in the treatment of metastatic colon cancer in the second-line setting and beyond.

Despite numerous clinical trials in the past, Prof Salem acknowledges the fact these trials have not shown any clinical benefit thus far.

However, he discusses the positive results achieved from several clinical trials, including the addition of regorafenib to oxaliplatin or irinotecan and the use of TAS-102 in this setting.

Prof Salem also notes the increased understanding of the biology of colorectal cancer as a recent major advancement - as oncologists can now differentiate between different types of the disease.

He believes that this field is moving towards precision medicine, with the help of recent advances in genetic testing.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation